» Articles » PMID: 36671488

In Vitro Models of Ovarian Cancer: Bridging the Gap Between Pathophysiology and Mechanistic Models

Overview
Journal Biomolecules
Publisher MDPI
Date 2023 Jan 21
PMID 36671488
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer (OC) is a disease of major concern with a survival rate of about 40% at five years. This is attributed to the lack of visible and reliable symptoms during the onset of the disease, which leads over 80% of patients to be diagnosed at advanced stages. This implies that metastatic activity has advanced to the peritoneal cavity. It is associated with both genetic and phenotypic heterogeneity, which considerably increase the risks of relapse and reduce the survival rate. To understand ovarian cancer pathophysiology and strengthen the ability for drug screening, further development of relevant in vitro models that recapitulate the complexity of OC microenvironment and dynamics of OC cell population is required. In this line, the recent advances of tridimensional (3D) cell culture and microfluidics have allowed the development of highly innovative models that could bridge the gap between pathophysiology and mechanistic models for clinical research. This review first describes the pathophysiology of OC before detailing the engineering strategies developed to recapitulate those main biological features.

Citing Articles

Cancer Organoids as reliable disease models to drive clinical development of novel therapies.

Blandino G, Satchi-Fainaro R, Tinhofer I, Tonon G, Heilshorn S, Kwon Y J Exp Clin Cancer Res. 2024; 43(1):334.

PMID: 39731178 PMC: 11681695. DOI: 10.1186/s13046-024-03258-7.


Multicompartmentalized Microvascularized Tumor-on-a-Chip to Study Tumor-Stroma Interactions and Drug Resistance in Ovarian Cancer.

Plesselova S, Calar K, Axemaker H, Sahly E, Bhagia A, Faragher J Cell Mol Bioeng. 2024; 17(5):345-367.

PMID: 39513004 PMC: 11538101. DOI: 10.1007/s12195-024-00817-y.


Paracrine Ovarian Cancer Cell-Derived CSF1 Signaling Regulates Macrophage Migration Dynamics in a 3D Microfluidic Model that Recapitulates In Vivo Infiltration Patterns in Patient-Derived Xenografts.

Scott A, Jazwinska D, Kulawiec D, Zervantonakis I Adv Healthc Mater. 2024; 13(28):e2401719.

PMID: 38807270 PMC: 11560735. DOI: 10.1002/adhm.202401719.


Vascularized tumor models for the evaluation of drug delivery systems: a paradigm shift.

Lopez-Vince E, Wilhelm C, Simon-Yarza T Drug Deliv Transl Res. 2024; 14(8):2216-2241.

PMID: 38619704 PMC: 11208221. DOI: 10.1007/s13346-024-01580-3.


Revolutionizing the female reproductive system research using microfluidic chip platform.

Yan J, Wu T, Zhang J, Gao Y, Wu J, Wang S J Nanobiotechnology. 2023; 21(1):490.

PMID: 38111049 PMC: 10729361. DOI: 10.1186/s12951-023-02258-7.


References
1.
Roland I, Yang W, Yang D, Daly M, Ozols R, Hamilton T . Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer. 2003; 98(12):2607-23. DOI: 10.1002/cncr.11847. View

2.
Das T, Meunier L, Barbe L, Provencher D, Guenat O, Gervais T . Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform. Biomicrofluidics. 2014; 7(1):11805. PMC: 3555942. DOI: 10.1063/1.4774309. View

3.
Lee Y, Jin J, Cheng C, Huang C, Song J, Huang M . Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013; 11(4):405-17. PMC: 3631285. DOI: 10.1158/1541-7786.MCR-12-0551. View

4.
Carduner L, Leroy-Dudal J, Picot C, Gallet O, Carreiras F, Kellouche S . Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins. Clin Exp Metastasis. 2014; 31(6):675-88. DOI: 10.1007/s10585-014-9658-1. View

5.
Kirkpatrick N, Brewer M, Utzinger U . Endogenous optical biomarkers of ovarian cancer evaluated with multiphoton microscopy. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):2048-57. DOI: 10.1158/1055-9965.EPI-07-0009. View